Wei Chen PhD WuXi Biologics

Wei Chen, Ph.D., MBA, is the Executive Director in Drug Product Development of WuXi Biologics, leading the Combination Product Team. He is a biopharmaceutical leader with over 20 years of expertise in CMC, spanning drug substance/product development, regulatory strategy, and commercialization. Having held pivotal roles at Eli Lilly, Gilead Sciences, Fresenius, Protagonist Therapeutics, and currently Wuxi Biologics, he has driven innovation in parenteral products (monoclonal antibodies, ADCs, peptides) and oral solid dosage forms, excelling in formulation, process optimization, and tech transfer.